Double Patenting: Old Tool For Generics And Biosimilars
A key area of concern for companies that produce generic drugs as well as companies likely to be involved in the Section 351(k) approval pathway for biosimilars has been how to...To view the full article, register now.
Already a subscriber? Click here to view full article